Enter your email to subscribe:

Drug and Device Law has a post on two recent New York Times articles -- one on DaVita's involvement with Epogen and possible resulting litigation, and the other on interpretation of scientific studies.

Point of law's Walter Olson has a post on a $2.4 billion lead-paint abatement plan submitted by the state after defendants' were held liable in a nuisance trial.